The bodys immune system is a beautiful and complex defense system designed to protect us from infections. In the case of multiple sclerosis and other autoimmune conditions, however, these defenses turn on the body.
In this feature, we investigate the complicated relationship between the immune system and multiple sclerosis (MS), as well as which way the causal relationship may lie.
In a person with MS, the immune system attacks axons or nerve fibers in the central nervous system (CNS), which are protected by an insulating layer called myelin.
MS damages these axons in the brain, spinal cord, and optic nerves, which send visual information from the eye to the brain.
The scar tissue that MS causes as a result of its attacks is visible in the brains white and gray matter. During an MS attack also called an exacerbation different types of immune cells damage or destroy most of the myelin within the targeted area.
Experts regard MS as an autoimmune disease, but the scientific community has not been able to identify any MS-specific antigens, which are proteins that prompt the immune system to attack.
Although much is still unknown, what do we know so far about the immune system and its role in MS?
Similar conditions to MS that are regarded as autoimmune diseases include:
With MS, we know that T cells which play an important part in the immune system become activated in the lymph system and then enter the CNS through blood vessels.
They then release chemicals that cause the damage associated with the condition, also activating B cells and other immune system cells to join the immune attack.
What scientists do not understand, however, is what finally knocks the immune system out of balance, allowing the T and B cells to become activated.
Experts consider conditions, such as MS, RA, lupus, type 1 diabetes, and celiac disease, to be examples of autoimmune diseases that are associated with the production of autoantibodies and self-reactive T cells.
However, with psoriasis, inflammatory bowel disease, or ankylosing spondylitis, immunity against these so-called self-antigens is not a feature, even though the immune system is involved.
The question that researchers must tackle in the wake of MS is: what could prevent these self-activating T cells from attacking the CNS?
To find out how to prevent such attacks from T cells, researchers are first attempting to unravel why they attack the CNS in the first place.
There are a few theories for why this occurs, according to the National Institute of Neurological Disorders and Stroke (NINDS).
One theory is that when the immune system is fighting an external invader such as a virus that mimics components of the brain, the immune system attacks CNS myelin in its attempts to quash the invader, a process known as molecular mimicry.
Another theory is that the immune system is destroying brain cells because they are unhealthy.
And yet another suggests the immune system simply mistakes normal brain cells for foreign invaders.
There is a blood-brain barrier (BBB) that keeps the brain and spinal cord separate from other substances in the body, including the immune system. However, if there is a breach of this barrier, the brain is then exposed to the immune system.
Experts say that in this case, the immune system may mistake myelin for a foreign invader.
Research has shown that the origins of MS point to both genetic predispositions combined with environmental factors. This is where the link between MS and infectious agents as environmental triggers comes to the fore.
Although many viruses have been found in people with MS, Epstein-Barr virus (EBV) is most consistently linked to the onset of the condition.
EBV is the virus that causes infectious mononucleosis, commonly known as mono, and it is one of the most common viruses in humans worldwide.
In fact, only about 5% of the population have not acquired infection with this virus. Researchers say people who have not contracted EBV are at a lower risk for developing MS than those who have.
Furthermore, people who contracted EBV in early childhood have a significantly lower risk for developing MS than those who did not contract the virus until adolescence or adulthood.
Contracting the virus later in life is typically accompanied by a more exaggerated immune response to EBV. Researchers say the higher MS risk suggests it might be the type of immune response to EBV that could lead to MS, rather than the virus infection itself.
But even this finding is shrouded in mystery for the moment because there is no proof that EBV actually causes MS, and the scientific community does not fully understand the workings behind the increased risk.
Given that MS is regarded as an autoimmune disease, many treatments for it naturally target or indeed harness the immune system.
One such treatment is beta interferon. Interferons are proteins that are naturally produced by the body to change the immune systems response to invaders.
White blood cells release gamma interferon at the start of an immune response, which encourages inflammation in the tissues being attacked.
On the other hand, beta interferon is released near the end of an immune response, blocking gamma interferon and helping reduce inflammation.
According to the Multiple Sclerosis Trust, beta interferon drugs can reduce the number of MS exacerbations and slow the progression of the disease. Furthermore, when exacerbations do occur, treatment with beta interferon drugs shortens them and reduces severity.
There is also an ongoing stem cell treatment clinical trial from the NINDS, called BEAT-MS. In this experimental trial, researchers are removing immune cells from participants and then infusing some of their own stem cells in an effort to reset their immune system so that it stops attacking the CNS.
With all of the studies in recent years dissecting the role of the microbiome in immunity, MS research has drilled down into the minutiae of gut bacteria.
One research team has looked at samples of blood, spinal fluid, and stool from people with MS, people without MS, and people with other disorders.
They have found that immune cells reacting to specific gut bacteria travel from the gut to the brain during MS exacerbations, potentially protecting the brain and reducing inflammation.
Their study in Science Immunology, which also looked at brain tissue from people who had MS in their life, showed that specific B cells targeted certain strains of gut bacteria linked to MS inflammation.
The team also found that during MS exacerbations but not during remissions these B cells traversed the BBB to MS brain lesions, releasing messenger chemicals that aim to reduce inflammation.
The authors note that it is unclear what activates the B cells to travel to the brain on a protective mission, but they say that if they find what activates that process, they could potentially use it to treat MS.
According to lead researcher Dr. Anne-Katrin Prbstel:
Apparently, these immune cells migrate from the intestine to the inflammation sites in the central nervous system, where they release an anti-inflammatory messenger substance. That could explain why the illness worsens if these immune cells are removed from the blood with medication.
While researchers are working to unravel this complicated condition and develop new treatments, there is one bright light that studies have repeatedly pointed to as being beneficial: the sun.
According to the NINDS, studies have shown that people who have higher levels of vitamin D and who spend more time in the sun are less likely to develop the condition.
For those with MS, it also means they are more likely to have a less severe form of the condition and fewer relapses.
We know that sunlight helps human skin make vitamin D, and researchers believe this vitamin helps modulate the immune system to reduce the risk of autoimmunity, including MS.
The research into the causes of MS and potential new treatments continues, as those who live with this condition emphasize its devastating impact on their quality of life.
Responding to interview questions for a BMJ study, one person with secondary progressive MS said that [i]ts like living your life with a weight on your back all the time, we cant do, we cant plan anything.
Therefore, the efforts to better understand MS and its mechanisms continue.
- FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz IND for Stroke Treatment - KPVI News 6 - May 14th, 2021
- Duluth health center specializes in regenerative medicine, hormone replacement therapy - Duluth News Tribune - May 14th, 2021
- Dr. Krger on Toxicities Associated With Allogeneic Stem Cell Transplant in Myeloma - OncLive - May 14th, 2021
- Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its... - May 14th, 2021
- Genenta Phase I/II Glioblastoma Data at ASGCT Show Temferon Delivered Tumor-Focused Interferon ExpressionData presented at the 2021 American Society... - May 14th, 2021
- ViaCyte To Participate In World Medical Innovation Forum Panel On Future Of Cell Therapy For Type 1 Diabetes - PRNewswire - May 14th, 2021
- Omeros' Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress - Business Wire - May 14th, 2021
- Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May - Business Wire - May 14th, 2021
- Outlook for multiple myeloma: Figures and factors that affect it - Medical News Today - May 14th, 2021
- Global Regenerative Medicine for Cartilage Market Report 2021: Companies are Continuously Focusing on Introducing New Technologies to Survive in the... - May 14th, 2021
- UB celebrates 175th anniversary of its origins in study of medicine - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter - May 14th, 2021
- Stem cell therapy for COVID-19 and ARDS - News-Medical.Net - May 7th, 2021
- Experimental COVID-19 lung treatment being tested at Ontario hospitals - CityNews Toronto - May 7th, 2021
- EP. 4: Optimizing Patient Selection for CAR T-Cell Therapy - OncLive - May 7th, 2021
- Could stem cells improve the outcome of ARDS in severe COVID-19? - News-Medical.Net - May 7th, 2021
- Motixafortide Reaches Primary End Point of Improved Stem Cell Mobilization in Multiple Myeloma Trial - Cancer Network - May 7th, 2021
- Restricting the Growth and Spread of Head and Neck Cancers - Technology Networks - May 7th, 2021
- The global stem cell therapy market is projected to reach USD 401 million by 2026 from - GlobeNewswire - May 7th, 2021
- UCLA team discovers how to restrict growth, spread of head and neck cancers | UCLA - UCLA Newsroom - May 7th, 2021
- NUS scientists found a key element that affects how genes are expressed in blood stem cells - Newswise - May 7th, 2021
- Citius Pharmaceuticals to Present Mino-Lok and COVID-related Respiratory Treatment Update at Benzinga Global Small Cap Conference on Thursday, May 13... - May 7th, 2021
- Mesoblast says its stem cell treatment saved lives of severely ill COVID patients - Stockhead - May 2nd, 2021
- Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants - News-Medical.Net - May 2nd, 2021
- Antiviral T cells protected, viable as off-the-shelf treatment for painful complication stem cells - Microbioz India - May 2nd, 2021
- Desperate family of boy, 9, with leukaemia have 10 days to save his life... - The Sun - May 2nd, 2021
- Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy - GlobeNewswire - May 2nd, 2021
- Investigating CAR T-Cell Therapy for Use in Different Disease Types - Targeted Oncology - May 2nd, 2021
- Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in... - May 2nd, 2021
- Thomas Smeenk on Hemostemix's autologous stem cell therapy technology and why some call it 'the fountain of youth' - InvestorIntel - April 28th, 2021
- Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer... - April 28th, 2021
- Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting - GlobeNewswire - April 28th, 2021
- Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low... - April 28th, 2021
- A review of baculovirus vectors in gene therapy | BTT - Dove Medical Press - April 28th, 2021
- Stem Cell Therapy for COPD: Hope and Exploitation - DocWire News - April 26th, 2021
- Axion BioSystems Announces Formation of Scientific Advisory Board - Business Wire - April 26th, 2021
- Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and... - April 24th, 2021
- Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment - DocWire... - April 24th, 2021
- Advancing the Development of Safe and Effective Regenerative Medicine Products | FDA - FDA.gov - April 24th, 2021
- New method helps map the specialized diversity and spatial location of cells within a tissue or tumor - News-Medical.Net - April 24th, 2021
- Chimeric embryo may have medical implications The Campus - The Campus - April 24th, 2021
- Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National... - April 24th, 2021
- Guenther Koehne, MD, Highlights Recent Advancements in the Treatment of Blood Cancers - Oncology Learning Network - April 24th, 2021
- Rinri Therapeutics raises 10 million to advance stem cell therapy for hearing loss - The Star - April 24th, 2021
- Cancer Diagnosis in Patient Given LentiGlobin Revised to Severe Anemia - Sickle Cell Anemia News - April 24th, 2021
- Hodgkin lymphoma: Symptoms, outlook, treatment, and more - Medical News Today - April 24th, 2021
- Tissue Repair, Mitochondrial Function and Wound Healing Explored in 2021 APS Presidents Symposium - Newswise - April 24th, 2021
- Axion BioSystems Announces Formation of Scientific Advisory Board - BioSpace - April 20th, 2021
- Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus - Proactive Investors USA - April 20th, 2021
- Rinri Therapeutics Raises 10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss -... - April 20th, 2021
- Global Regenerative Medicines Market 2020-2030: Opportunities in Drug Approvals and Strong Pipeline of Cell and Gene Therapies & Multiple... - April 20th, 2021
- FDA Grants Orphan Drug Status to Novel IRAK4 Inhibitor in AML and MDS - Targeted Oncology - April 20th, 2021
- Vertex Drops $900 Million to Expand Partnership with CRISPR Therapeutics - BioSpace - April 20th, 2021
- Kaleido Biosciences Announces Collaboration with Robert Jenq, MD, to Explore Potential of its Microbiome Metabolic Therapies (MMT) in Preventing... - April 20th, 2021
- Partner Content | Being bionic: the future of regenerative medicine - TheSpec.com - April 14th, 2021
- Ohio State Recruits Top Oncologist to Expand Cell Therapy Program, Lead Bone Marrow Transplant Services - Wexner Medical Center - The Ohio State... - April 14th, 2021
- Leukemia Cutis: Symptoms and Treatment - Healthline - April 14th, 2021
- Green: Variants and outbreaks continue to put stress on hospitals - Vermont Biz - April 14th, 2021
- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends - GlobeNewswire - April 14th, 2021
- Consortium to investigate role of neurofilament light chain in neurodegenerative diseases Washington University School of Medicine in St. Louis -... - April 14th, 2021
- Man's heart healed by stem cell therapy and love of an old flame - Leeds Live - April 12th, 2021
- New pediatric cancer treatment method being used in Iran - Tehran Times - April 12th, 2021
- Personalized Cancer Vaccine Shows Early Efficacy in Patients With Diverse Tumor Types - Technology Networks - April 12th, 2021
- 1000th Stem Cell Transplant Given to Girl Who Is One in a Million - Stanford Children's Health Blog - Stanford Children's Health - April 10th, 2021
- Home : Stem Cell Treatments - April 10th, 2021
- Researchers discover unique regenerative property of cells in the early human embryo - News-Medical.net - April 10th, 2021
- Study reveals sex-differences in aging of the brain stem cell niche - News-Medical.net - April 10th, 2021
- Antibiotics need further study in cancer treatments - Chicago Daily Herald - April 10th, 2021
- Prolonged infection and inflammation drain immune responses as we age - Baylor College of Medicine News - April 10th, 2021
- Toward a transformative therapy for sickle cell patients - News-Medical.Net - April 10th, 2021
- Mass. Residents 55+ Or With 1 Medical Condition Can Now Get COVID Vaccine | WBZ NewsRadio 1030 - iHeartRadio - April 6th, 2021
- Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - DocWire News - April 6th, 2021
- BioRestorative Therapies Announces Appointment of Nickolay V. Kukekov, Ph.D to its Board of Directors - BioSpace - April 6th, 2021
- LGL Leukemia: Overview, Symptoms, and Treatment - Healthline - April 3rd, 2021
- Novel T-Cell Therapy MT-401 Under Evaluation in Post-Transplant AML - OncLive - April 3rd, 2021
- Funding the Next Generation of Cancer Therapies - Genetic Engineering & Biotechnology News - April 3rd, 2021
- Do Therapies for Alzheimer's & Parkinson's that Clear Abnormal Brain Proteins Make the Diseases Worse? - BioSpace - April 3rd, 2021
- Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy - DocWire News - April 1st, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 1st, 2021
- The Government's Watchful Eye on Fraud Stemming from Stem Cell Therapy - Lexology - April 1st, 2021
- Introducing a neuro regenerative gene into mice with spinal cord injury improves motor function - News-Medical.net - April 1st, 2021